IP Library Granted Patent US 12,370,199
Granted Patent B2
US 12,370,199 · App. 17/379,534 · Granted Jul 29, 2025

Fulvestrant formulations and methods of their use

Inventors: Feng-Jing Chen (Irvine, CA); Steven L. Krill (Midland Park, NJ); Rama Abu Shmeis (Branchburg, NJ)
Assignee: Eagle Pharmaceuticals, Inc.
A61K31/565A61K9/0019A61K9/08A61K9/10A61K9/14A61K31/519A61K45/06A61K47/10A61K47/26A61K47/32A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,199
App. No.
17/379,534
Granted
Jul 29, 2025
Kind
B2
Abstract

The disclosure is directed to fulvestrant formulations including suspensions of fulvestrant particles suitable for injection. The formulations can comprise fulvestrant particles having an LD Dv(10) less than about 3 microns, for example, between about 1 micron to about 3 microns, an LD Dv(50) less than about 35 microns, for example, between about 2 microns and about 35 microns, and an LD Dv(90) less than about 120 microns, for example, between about 4 microns and about 120 microns. The formulations can comprise fulvestrant particles having a CE Dv(90) less than about 200 microns, for example, between about 10 microns and about 200 microns, a CE Dv(50) less than about 60 microns, for example, between about 5 microns and about 60 microns, and a CE Dv(10) less than about 25 microns, for example, between about 1 microns and about 25 microns.

Claims (18)

1. A method of forming an aqueous fulvestrant suspension comprising:

mixing an aqueous medium and at least one stabilizer to form a suspension vehicle, the at least one stabilizer comprising:

a surfactant and

a polyvinylpyrrolidone, polyethylene glycol with an average molecular weight of about 3350 g/mol, a carboxymethylcellulose sodium, a non-electrolyte, or a combination thereof;

adding an amount of fulvestrant to the suspension vehicle; and

dispersing the fulvestrant in the suspension vehicle to form an aqueous fulvestrant suspension;

wherein the aqueous fulvestrant suspension comprises fulvestrant particles having one or more of:

a laser diffraction determined (LD) Dv(10) from about 1 micron to about 3 microns;

an LD Dv(50) from about 2 microns to about 35 microns; and

an LD Dv(90) from about 4 microns to about 120 microns;

and having one or more of:

a microscopy image capture determined (CE) Dv(90) from about 10 microns and about 200 microns;

a CE Dv(50) from about 5 microns to about 60 microns; and

CE Dv(10) from about 1 microns to about 25 microns.

2. The method of claim 1 , further comprising high pressure homogenizing the aqueous fulvestrant suspension.

3. The method of claim 2 , wherein the high pressure homogenization is performed at a pressure of about 15,000 psi to about 45,000 psi.

4. The method of claim 2 , further comprising adding an electrolyte to the homogenized aqueous fulvestrant suspension and mixing the electrolyte into the suspension.

5. The method of claim 2 , further comprising adding another non-electrolyte to the homogenized aqueous fulvestrant suspension and mixing the other non-electrolyte into the suspension.

Assignments (3)
GRANT OF SECURITY INTEREST Recorded Feb 18, 2026
From: EAGLE PHARMACEUTICALS, INC
To: ANKURA TRUST COMPANY, LLC.
Reel/Frame 074849/0457 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 070703/0524 →
SECURITY INTEREST Recorded Nov 1, 2022
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 061615/0013 →
Continuity (4)
Continuation 16099265
Provisional Application 62420555 · Nov 10, 2016
Provisional Application 62332842 · May 6, 2016
Related Publication 20210346396A1 · Nov 11, 2021
References Cited (111)
US 6774122B2 · Evans et al. · 2004 [cited by applicant]
US 7456160B2 · Evans et al. · 2008 [cited by applicant]
US 8158152B2 · Palepu · 2012 [cited by applicant]
US 8329680B2 · Evans et al. · 2012 [cited by applicant]
US 8466139B2 · Evans et al. · 2013 [cited by applicant]
US 8541400B2 · Johnsson et al. · 2013 [cited by applicant]
US 8586092B2 · Hu et al. · 2013 [cited by applicant]
US 8853260B2 · Desai et al. · 2014 [cited by applicant]
US 8956659B2 · Hu et al. · 2015 [cited by applicant]
US 9180088B2 · Palepu · 2015 [cited by applicant]
US 9254268B2 · Temtsin et al. · 2016 [cited by applicant]
US 9271990B2 · Faraj · 2016 [cited by applicant]
US 20010020016A1 · Evans et al. · 2001 [cited by applicant]
US 20030114430A1 · Macleod et al. · 2003 [cited by applicant]
US 20030165568A1 · Colombo et al. · 2003 [cited by applicant]
US 20030185568A1 · Ooi et al. · 2003 [cited by applicant]
US 20060251582A1 · Reb · 2006 [cited by applicant]
US 20070093547A1 · Desai et al. · 2007 [cited by applicant]
US 20080161276A1 · Johnsson et al. · 2008 [cited by applicant]
US 20090098200A1 · Temtsin et al. · 2009 [cited by applicant]
US 20100166872A1 · Singh et al. · 2010 [cited by applicant]
US 20100323020A1 · Gokhale et al. · 2010 [cited by applicant]
US 20130033813A1 · Ling et al. · 2013 [cited by applicant]
US 20130267489A1 · Teja et al. · 2013 [cited by applicant]
US 20130274236A1 · Swart · 2013 [cited by applicant]
US 20130338131A1 · Staric et al. · 2013 [cited by applicant]
US 20140088061A1 · Castillo et al. · 2014 [cited by applicant]
US 20140314664A1 · Qin et al. · 2014 [cited by applicant]
US 20150104521A1 · Desai et al. · 2015 [cited by applicant]
US 20150132388A1 · Angi et al. · 2015 [cited by applicant]
US 20150231153A1 · Faraj · 2015 [cited by applicant]
US 20160058773A1 · Palepu · 2016 [cited by applicant]
US 20160129014A1 · Faraj · 2016 [cited by applicant]
US 20160220505A1 · Temtsin et al. · 2016 [cited by applicant]
CN 1429101A · 2003 [cited by applicant]
CN 101108168A · 2008 [cited by applicant]
CN 102802609A · 2012 [cited by applicant]
CN 104337761A · 2015 [cited by applicant]
EP 1962906 · 2008 [cited by applicant]
EP 2200588 · 2010 [cited by applicant]
EP 2249839 · 2010 [cited by applicant]
EP 2460539A1 · 2012 [cited by applicant]
EP 2601935A1 · 2013 [cited by applicant]
EP 2616078 · 2013 [cited by applicant]
EP 2661281 · 2013 [cited by applicant]
EP 3068377 · 2016 [cited by applicant]
JP 2003519659A · 2003 [cited by applicant]
JP 2004534093A · 2004 [cited by applicant]
TW 201016220A · 2010 [cited by applicant]
WO 0187266A1 · 2001 [cited by applicant]
WO 0306064 · 2003 [cited by applicant]
WO 2006013369A2 · 2006 [cited by applicant]
WO 2007061529A1 · 2007 [cited by applicant]
WO 2007069272A2 · 2007 [cited by applicant]
WO 2009040818A1 · 2009 [cited by applicant]
WO 2009111057A2 · 2009 [cited by applicant]
WO 2010147899A1 · 2010 [cited by applicant]
WO 2012021791A2 · 2012 [cited by applicant]
WO 2012035516A1 · 2012 [cited by applicant]
WO 2012094620A2 · 2012 [cited by applicant]
WO 2013153559A1 · 2013 [cited by applicant]
WO 2015033302A2 · 2015 [cited by applicant]
WO 2015051193A1 · 2015 [cited by applicant]
WO 2015071836A1 · 2015 [cited by applicant]
WO 2015114320A1 · 2015 [cited by applicant]
WO 2016000653A1 · 2016 [cited by applicant]
WO 2016004369A1 · 2016 [cited by applicant]
Addo et al., A phase 1 trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers, British Journal of Cancer, 87, 2002, 1354-1359. [cited by applicant]
Ballard, B., “Biopharmaceutical considerations in subcutaneous and intramuscular drug administration”, Journal of Pharmaceutical Sciences, 1968, 57(3):357-378. [cited by applicant]
Behre, H., et al., “Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies”, 1999, 140(5):414-419. [cited by applicant]
Brunner, N. “MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780”, Cancer Res. 1993, 53(14):3229-3232. [cited by applicant]
Chatterjee et al., Contrasting action of antiestrogen (ICI-182780) for preventing initiation of embryo implantation by estradiol or epidermal growth factor (EGF). Life sciences, Jan. 1, 1993;53(21):1625-1630. [cited by applicant]
DeFriend et al., Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Research. Jan. 15, 1994;54(2):408-414. [cited by applicant]
Dukes et al., Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys, Journal of Endocrinology. Nov. 1, 1992;135(2):239-247. [cited by applicant]
Dukes et al., Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys ( [cited by applicant]
Gallagher et al., The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology. Dec. 1, 1993;133(6):2787-2791. [cited by applicant]
Gradishar et al., Clinical potential of new antiestrogens. Journal of Clinical Oncology. Feb. 1997;15(2):840-852. [cited by applicant]
Gunther et al., The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatric research. Sep. 1999;46(3):269-273. [cited by applicant]
Howell et al., Clinical studies with the specific ‘pure’ antioestrogen ICI 182780. The Breast. Jun. 1, 1996;5(3):192-195. [cited by applicant]
Hu et al., Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780. International journal of cancer, Nov. 11, 1993;55(5):873-876. [cited by applicant]
ISO 13320, International Standard, Particle size analysis—Laser diffraction methods; First edition, Oct. 1, 2009, 58 pages. [cited by applicant]
Kern, F. et al., “Transfected MCF-7 cells as a model for breast cancer progression”, Breast Cancer Research and Treatment, 1994, 153-165. [cited by applicant]
Kuter et al., Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study, Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 26, No. 15S, (May 20 … [cited by applicant]
Langdon, S. et al., “Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model”, Eur J Cancer, 1994, 682-686. [cited by applicant]
McClelland, R. et al., “Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes”, Breast Cancer Research Treatment, 1996, 41… [cited by applicant]
McClelland, R. et al., “Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast canc… [cited by applicant]
Minto, C., et al., “Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume”, The Journal of Pharmacology and Experimental Therapeutics, 1997, 281… [cited by applicant]
Nicholson, R. et al., “Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer”, Annals New York Academy of Sciences, 1995, 12;761:148-163. [cited by applicant]
Ogasawara , Y. et al., “Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice”, Surgery Today, 1999, 29, 149-156. [cited by applicant]
Ohno et al., Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1), Annals of Oncology 21: 2342-2347, 2010. [cited by applicant]
Osborne, C. et al., “Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer”, Journal of the National Cancer Institute, 1995, 746-750. [cited by applicant]
Osborne, C., et al., “The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth”, Cancer Chemother Pharmacol, 1994, 89-95. [cited by applicant]
Parczyk, K., et al., “Progesterone receptor repression by estrogens in rat uterine epithelial cells”, J Steroid Biochem Mol Biol., 1997, 63(4-6):309-316. [cited by applicant]
Parisot, J. et al., “The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor”, Int J Cancer, 1995, 62(4):480-4. [cited by applicant]
Robertson et all., Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer, Clin. Pharmacokinet, 43(8), 2004, 529-538. [cited by applicant]
Robertson, Fulvestrant: pharmacokinetics and pharmacology; British Journal of Cancer, 90 (Suppl I), 2004, S7-S10. [cited by applicant]
Sahlin, L., et al., “Regulation of thioredoxin mRNA in the rat uterus by gonadal steroids”, Journal of Steroid Biochemistry & Molecular Biology, 1999, 68(5-6):203-209. [cited by applicant]
Spiegel, A., et al., “Use of Nonaqueous Solvents in Parenteral Products”, Journal of Pharmaceutical Sciences, 1963, 52, 917-927. [cited by applicant]
Thurlimann, B., “Hormonal treatment of breast cancer: new developments”, Oncology, 1998, 55(6):501-507. [cited by applicant]
Vollmer, G., et al., “The rat endometrial adenocarcinoma cell line RUCA-I: a novel hormone-responsive in vivo/in vitro tumor model”, J Steroid Biochem Mol Biol. 1996, 58(1):103-115. [cited by applicant]
Von Minckwitz, G. et al., “New endocrine approaches in the treatment of breast cancer”, Biomed Pharmacother, 1998, 52(3):122-132. [cited by applicant]
Wakeling AE. A new approach to breast cancer therapy: Total estrogen ablation with pure antiestrogens, Long-Term Tamoxifen Treatment for Breast Cancer, ed Jordan VC (University of Wisconsin Press, Madison). 1994:219-234. [cited by applicant]
Wakeling, A., “Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?”, The Journal of Steroid Biochemistry and Molecular Biology, 1993, 107-114. [cited by applicant]
Wakeling, A., “Interactions Between Growth Factors and Oestrogens in Breast Cancer Cells”, Molecular Oncology and Clinical Applications, 1993, 385-389. [cited by applicant]
Wakeling, A., “The future of new pure antiestrogens in clinical breast cancer”, Breast Cancer Res Treat. 1993, 25(1):1-9. [cited by applicant]
Wakeling, A., et al., “Development of novel oestrogen-receptor antagonists”, Biochem Soc Trans, 1991, 19(4):899-901. [cited by applicant]
Wakeling, A., et al., “ICI 182,780, a new antioestrogen with clinical potential”, J Steroid Biochem Mol Biol. 1992, 43(1-3):173-177. [cited by applicant]
Wilson, J. et al., “MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage”, Int J Cancer, 1995 , 61(4):502-508. [cited by applicant]
Zalcberg, J. et al., “Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines”, Cancer Chemother Pharmacol. 1993;33(2):123-129. [cited by applicant]
“Polyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution”, Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ef00202d-7a97-43df-adc7-c4043b54df03, Retrieved on Feb. 18, … [cited by applicant]
“Polyethylene Glycol 3350”, Revision Bulletin, Dec. 1, 2020, 7 Pages. [cited by applicant]